DCM
BTAI icon

DAFNA Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

DAFNA Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-288
Closed -$103K – 89
2020
Q1 		$103K Buy
+288
New +$104K 0.04% 77
2019
Q4 		– Sell
-7,969
Closed -$898K – 83
2019
Q3 		$898K Buy
+7,969
New +$1.26M 0.34% 61

Other funds holding BTAI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

DAFNA Capital Management's BTAI Position: Q2 2020 in Review

DAFNA Capital Management sold out of BioXcel Therapeutics (BTAI) in Q2 2020, closing a stake of 288 shares — an estimated $103K sold.

DAFNA Capital Management first reported a position in BTAI in Q3 2019 and held it in 2 quarters. The position peaked at $898K in Q3 2019. 104 funds tracked by Wall St. Rank hold BTAI as of Q2 2020.

  • DAFNA Capital Management reported no remaining BioXcel Therapeutics position as of Q2 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 288 BioXcel Therapeutics shares in Q2 2020, an estimated $103K.
  • DAFNA Capital Management first reported a position in BioXcel Therapeutics in Q3 2019 and held it in 2 quarters.
  • DAFNA Capital Management's BioXcel Therapeutics position peaked at $898K in Q3 2019.
  • 104 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2020.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.